Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH („Eternygen“) by becoming an investor in addition to being a pre-clinical drug discovery partner. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-eternygen-to-develop-novel-metabolic-disease-therapy-5426